Get the Stockscreener App
1.25
3.10%
-0.04
After Hours:
1.24
-0.01
-0.80%
Rani Therapeutics Holdings Inc stock is traded at $1.25, with a volume of 450.33K.
It is down -3.10% in the last 24 hours and down -16.11% over the past month.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
See More
Previous Close:
$1.29
Open:
$1.3
24h Volume:
450.33K
Relative Volume:
0.21
Market Cap:
$121.94M
Revenue:
$1.20M
Net Income/Loss:
$-52.41M
P/E Ratio:
-1.3736
EPS:
-0.91
Net Cash Flow:
$-31.25M
1W Performance:
+13.64%
1M Performance:
-16.11%
6M Performance:
+135.40%
1Y Performance:
-26.04%
1-Day Range:
$1.21
$1.3177
1-Week Range:
$1.11
$1.415
52-Week Range:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Name
Rani Therapeutics Holdings Inc
Sector
Industry
Phone
(408) 457-3700
Address
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
1.25 | 125.84M | 1.20M | -52.41M | -31.25M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Jun-14-24 | Initiated | Maxim Group | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jul-27-22 | Initiated | H.C. Wainwright | Buy |
| Jun-13-22 | Initiated | Wedbush | Outperform |
View All
Rani Therapeutics Holdings Inc Stock (RANI) Latest News
Is Rani Therapeutics Holdings Inc. stock near bottom after decline2025 Year in Review & Consistent Growth Equity Picks - mfd.ru
Rani Therapeutics Holdings Inc. (RANI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Income Plays: What is the next catalyst for Rani Therapeutics Holdings IncWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Published on: 2026-02-02 11:44:32 - baoquankhu1.vn
What is the next catalyst for Rani Therapeutics Holdings IncWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Insider Buyers At Rani Therapeutics Holdings Sitting On US$1.3m Profit - simplywall.st
Rani Therapeutics promotes Alireza Javadi to chief technical officer By Investing.com - Investing.com South Africa
Rani Therapeutics Holdings, Inc. Announces Promotion of Alireza Javadi to Chief Technical Officer - marketscreener.com
Rani Therapeutics announces the promotion of Alireza Javadi, Ph.D. to chief technical officer - marketscreener.com
Rani Therapeutics Names Alireza Javadi Chief Technical Officer - Nasdaq
Rani Therapeutics promotes Alireza Javadi to chief technical officer - Investing.com
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer - The Manila Times
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bear Alert: Does CompoSecure Inc Equity Warrant stock have upside surprise potential2025 Sector Review & Daily Stock Trend Watchlist - baoquankhu1.vn
Published on: 2026-01-24 03:15:13 - baoquankhu1.vn
AI Stocks: Does XBiotech Inc offer margin of safety2025 Macro Impact & Short-Term High Return Ideas - baoquankhu1.vn
Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17% - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Ardelyx (ARDX) and AxoGen (AXGN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY) - The Globe and Mail
Rani Therapeutics finalizes governance and capital structure changes - MSN
Targets Report: Can Rani Therapeutics Holdings Inc navigate macro headwindsJuly 2025 Chart Watch & Consistent Return Investment Signals - baoquankhu1.vn
Price Action: Can Rani Therapeutics Holdings Inc navigate macro headwinds2025 Technical Patterns & Community Supported Trade Ideas - baoquankhu1.vn
HOKA Shoe Comparison: Will Rani Therapeutics Holdings Inc. stock outperform tech sector in 2025Grip and Outsole Review & quick comparison of popular models - Улправда
HC Wainwright Reaffirms Buy Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat
RANI: HC Wainwright Reiterates Buy Rating with $11 Target | RANI Stock News - GuruFocus
Is Rani Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Summary & Consistent Return Investment Signals - Улправда
How Rani Therapeutics Holdings Inc. stock reacts to inflationary pressuresTrade Risk Report & Long-Term Investment Growth Plans - Улправда
How Rani Therapeutics Holdings Inc. stock compares to growth peersJuly 2025 Chart Watch & Verified Momentum Stock Watchlist - Улправда
Can Rani Therapeutics Holdings Inc. stock sustain revenue growthQuarterly Profit Report & Verified Momentum Stock Alerts - Улправда
Can Rani Therapeutics Holdings Inc. stock hit record highs againQuarterly Profit Review & Growth Focused Entry Point Reports - Улправда
Aug Intraday: Is Rani Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Volume & Scalable Portfolio Growth Methods - Улправда
Rani Therapeutics begins phase 1 trial of oral obesity treatment By Investing.com - Investing.com Australia
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen - The Manila Times
Rani Therapeutics begins phase 1 trial of oral obesity treatment - Investing.com
Rani Therapeutics Initiates Phase 1 Study of RT-114 - GlobeNewswire
Can Rani Therapeutics Holdings Inc. stock rebound after recent weaknessMorning Star Patterns & Invest Now - Улправда
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Rani Therapeutics amends charter, reduces Class B voting power and ends tax agreement - Investing.com Nigeria
Rani Therapeutics Holdings Inc Stock (RANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):